However, CXCL16, a CXCR6 ligand gene regulated by IFN and TNF signaling pathways, also showed significantly high expression in bone marrow cells and mast cells (Xiao et al., 2015), suggesting that CXCR6 inhibition could be a potential therapeutic target to reduce the metastasis of cancer cells and effectively improve intestinal inflammation. This evidence concerns the gene CXCL16 and cancer.